This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Stocks · News reference
8-K filing — LB PHARMACEUTICALS INC (LBRX)
Filed: 2026-09-15 AccNo: 0001193125-26-391358 Size: 174 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68
Needham analyst Ami Fadia initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $68.
LB Pharmaceuticals Files Prospectus For Offering Mixed Shelf; Terms Undisclosed